消积饮维持治疗晚期肺癌及其对PI3K/AKT/mTOR信号通路影响的研究
|
摘要
研究背景：
肺癌是全球常见的恶性肿瘤之一,并成为目前人类因癌症死亡的主要原因,是对人类健康与生命危害最大的恶性肿瘤之一。PI3K/AKT/mTOR信号通路在肺癌的发生发展中起着重要的作用,该通路的活化可以抑制多种刺激诱发的细胞凋亡,促进细胞周期进展,从而促进细胞的生长和增殖,同时参与血管形成,在肺癌的形成中扮演重要角色,并参与肿瘤的侵袭和转移。
维持治疗作为延长肺癌患者长期生存的新的重要手段,已引起临床医生的极大重视。晚期非小细胞肺癌的维持治疗临床研究表明,患者经过4-6周期含铂类药物的一线标准联合化疗方案后,疾病无进展且体力状况良好,选择毒副作用较小的药物如细胞毒单药维持化疗或分子靶向药物进行维持治疗可使晚期非小细胞肺癌(NSCLC)患者受益。而中药在维持治疗晚期非小细胞肺癌的领域中的研究尚为数不多,基于长期化疗药物及分子靶向药物维持治疗的毒副反应,中医药可发挥自身优势,探索最佳维持治疗方案。
消积饮作为广东省中医院名老中医刘伟胜教授的多年经验方,已取得了良好的临床疗效,同时亦有多个实验证明该药能够抑制小鼠Lewis肺癌的生长和自发性肺转移、延长荷瘤小鼠的生存期,其作用机制与消积饮降低小鼠Lewis肺癌细胞cyclinDl的表达,影响其细胞周期G1/S调控点,有效地阻止肿瘤细胞周期于G0、G1期,使其不能进入S期进行DNA复制有关。此外,消积饮能有效下调肿瘤细胞PCNA(增殖细胞核抗原)、survivin蛋白及bcl-2基因的表达强度,诱导肿瘤细胞凋亡,降低其转移潜能,从而稳定病灶、减少转移。研究目的：
为探索一条中药维持治疗晚期肺癌的治疗方案,同时深层次挖掘名老中医的学术内涵,从PI3K/AKT/mTOR信号通路探讨消积饮抑制肺癌生长的分子机制亟待进一步研究。
研究内容与方法：
1临床部分
根据纳入标准选入64例经4～6周期化疗后1个月以上,RECIST评价稳定的ⅢB及Ⅳ期NSCLC患者,入组前患者卡氏评分≥60分,无脑转移或脑转移无症状,骨髓、心、肝、肾功能正常。按信封法随机分为治疗组和对照组各32例,治疗组给予消积饮(60ml/m2, po, qd)维持治疗,对照组给予支持治疗,治疗3月后对照统计两组维持治疗的有效率(CR+PR+SD)、临床证候及体力状况、疾病无进展生存期(PFS)及总生存期(OS)。治疗组评价无疾病进展继续治疗及随访观察至疾病进展或死亡。应用SPSS12.0统计分析软件,组间临床特征均衡性评估采用方差分析和PearsornX2检验；组间OS、PFS比较采用Kaplan-Meier分析；治疗后临床证候、体力状况评分取治疗后评估分。组间症状缓解率、体力状况比较采用两个独立样本Mann-Whitney U Test。安全性评价采用描述性统计。
2实验部分
选取人A549肺癌细胞株作为研究对象,生长于RPMI-1640培养液中,细胞传代24h进入对数生长期后分别加入低浓度、中浓度、高浓度含药血清(含消积饮的大鼠血清)及胎牛血清对照组进行细胞诱导。MTS法测定消积饮对A549细胞增殖的抑制作用,Western Blot印迹法检测PI3K/AKT通路p-AKT蛋白的表达,RT-PCR法检测含药血清对PI3K/AKT通路下游分子BAD、Caspase-9、FKHR等基因的mRNA的表达。应用SPSS12.0统计分析软件,组间对照采用单因素方差分析和t检验。
研究结果：
1临床部分
1.1临床特征
64例PSO-2的ⅢB/Ⅳ期非小细胞肺癌患者均来自于广东省中医院肿瘤科住院部,患者于2008年9月到2010年12月纳入研究,治疗前两组基线资料,性别、吸烟史、年龄、分期、KPS评分、入组前化疗等差异均无显著性,组间分布均衡(P>0.05)。共4例出组,治疗组2例因未完成既定治疗出组,对照组2例因主观违背治疗方案出组。实际可评价疗效病例60例,已死亡41例,其余19例正在随访中,按预期计划,经统计学样本数估算,符合疗效评价要求。
1.2近期疗效
治疗3个月后疗效评估,消积饮治疗组有效率达76.7%,对照组有效率达43.3%,两组之间相比具有显著差异(P=0.00)。
1.3生存时间
截止最后随访时间,治疗组和对照组OS分别为6.43个月和3.27个月,组间比较,治疗组的OS延长了3.16个月,两组有明显差异(P=0.00)；治疗组和对照组PFS分别为5.07个月和2.53个月,组间比较,治疗组的PFS延长了2.54个月,两组有明显差异(P=0.00)。
1.4临床证候评分
治疗3个月后,与对照组比较,治疗组临床证候评估改善率提高了43.3%,差异有统计学意义(Z=2.362,P=0.009)。1.5体力状况
治疗3个月后,与对照组比较,治疗组体力状况改善率提高了26.6%,差异有统计学意义(Z=2.128,P=0.033)。
1.6安全性评价安全性评价表明受试者服用消积饮前后血常规,肝、肾功能及心电图检查均未见明显变化。按WHO《实体瘤疗效评定标准和急性和亚急性毒副反应评定标准》,本组病例中没有出现因为不能耐受不良反应而出组的情况。未见相关血液学毒性。未见明显呕吐、腹泻等胃肠道症状、脱发及严重的心、肝、肾功能损害。治疗组3例受试者第2天出现恶心,按WHO毒性分级1级,未经处理,持续约10min,后症状消失；1例受试者服药后约30min出现轻度腹泻,未经处理自行缓解。未出现与治疗相关的死亡。
2实验部分
2.1 MTS法检测含不同浓度消积饮血清对细胞增殖影响的研究
不同浓度的消积饮血清均可抑制人A549肺癌细胞的增殖；高浓度消积饮血清培养人A549肺癌细胞72小时增殖抑制率与对照组相比具有显著差异。
2.2消积饮调控人肺癌细胞p-PI3K/p-AKT/mTOR基因表达的研究
人A549肺癌细胞中加入不同浓度的消积饮血清作用48小时、72小时后记录基因表达量,结果示BAD、Caspase-9基因mRNA的表达量明显增加,作用48小时的高浓度消积饮组2-△△Ct较对照组明显升高,并具有统计学意义(P<0.01)；各实验组之间比较无明显差异。同时,mTOR、NF-κB、FKHR基因mRNA的表达量也明显增加,较对照组也具有统计学意义(P<0.01)；各实验组之间比较无明显差异(P>O.05)。2.3 Western Blotting检测消积饮对PTEN、PI3K及p-AKT蛋白表达的影响
经图像处理分析,以GAPDH的灰度值为参照,PTEN、P13K、磷酸化AKT的蛋白表达减少,PI3K的蛋白表达量增加；其中低、中浓度消积饮组可使p-PTEN表达下调,与对照组相比有明显差异(P<0.01)；低、高浓度消积饮组可使P-PI3K表达上调,与对照组相比有明显差异(P<0.01)；中、高浓度消积饮均可使磷酸化AKT蛋白表达水平下调,与对照组相比具有统计学意义(P<0.01)。
研究结论：
1临床部分
本研究通过前瞻性随机对照试验,消积饮治疗组的有效率较对照组明显升高,中位生存时间及疾病无进展时间较对照组明显延长,临床证候与体力状况较对照组明显改善,毒副反应轻微,安全性评价高。因此,消积饮作为晚期非小细胞肺癌的中药维持治疗方案具有有效低毒的优势,可使晚期NSCLC患者的生存时间及生活质量获益。
2实验部分
消积饮含药血清可在体外有效抑制人肺癌细胞株A549细胞的增殖,具有一定的细胞毒性作用；消积饮可有效抑制PI3K/AKT信号转导通路的AKT位点,增加PI3K/AKT信号转导通路的下游分子BAD、Casepase-9基因mRNA的表达,促进A549肺癌细胞的凋亡,从而有效抑制A549肺癌细肺癌的生长。
Objectives
To investigate a treatment regime of Traditional Chinese Medicine (TCM) as a maintenance therapy for advanced Non-small cell Lung Cancer (NSCLC), to deepen the discovery in the academic content of renowned old TCM practitioner Liu Wei-sheng, and to further investigate the molecular mechanism of XiaoJiYin in suppressing lung cancer growth through the PI3K/AKT/mTOR pathway.
Methods
1 Clinical study
Sixty-four patients of advanced NSCLC were included according to the inclusion criteria, and were randomly divided into treatment group and control group, with 32 patients respectively. In the treatment group, XiaoJiYin was given as a maintenance therapy (60ml/m2, po, qd), while only follow-up and observation was given in the control group (Best support care). After 3 months treatment, the response rate, clinical syndrome scores, KPS scores, overall survival (OS) and progression-free survival (PFS) were compared between the two groups. Variance analysis was performed for the clinical characteristics between groups, while Kaplan-Meier analysis was conducted for the comparison of OS and PFS.
2 Experimental study
Human A549 lung cancer cell line was selected. It was cultivated in RPMI-1640, and XiaoJiYin containing rat serum of low, medium and high concentrations, and fetal bovine serum (FBS) as a control, were added to the cells in logarithmic phase for cell induction. MTS method was used for the suppressive effect of XiaoJiYin in A549 cell proliferation. Western-blot was used for the detection of p-AKT protein in PI3K/AKT pathway, and RT-PCR was used in detecting the expression of downstream mRNA, such as BAD, Caspase-9, FKHR, mTOR and NF-K B in the PI3K/AKT pathway. Variance analysis was performed between groups.
Results
1 Clinical study
1.1 Patient characteristics
The 64 cases of stage IIIB/IV NSCLC patients with PSO-2 were recruited from the In-patient Oncology Department of Guangdong Provincial Hospital of TCM. Patients were enrolled during September 2008 and December 2010. The pre-enrolment baseline characteristics, such as sex, smoking history, age, staging, KPS score and chemotherapy regimens received, had no significant difference and was balanced between groups (P>0.05). Four cases were drop-off, in which the 2 cases in treatment group withdrew due to discontinuation of treatment, while the 2 cases in the control group withdrew because of change in self-decision. There were 60 evaluable cases, 41 cases deceased, while follow-up was conducting. According to the plan, through statistical evaluation of sample number, the requirement of therapeutic evaluation was reached.
1.2 Short-term Efficacy
Therapeutic evaluation was conducted after 3 months of treatment. The response rate (RR) was 76.6% in the treatment group, while the disease control rate (DCR) was 43.3% in the control group. There was significant difference between the 2 groups (P=0.00).
1.3 Survival
Up to the last follow-up, the overall survival (OS) was 6.43 months and 3.27 months in the treatment and control groups respectively. Intra-group comparison suggested that the OS was extended for 3.16 months in the treatment group, indicating significant difference between the 2 groups (P=0.00). The progression-free survivals (PFS) were 5.07 months and 2.53 months in the treatment group and control group respectively. Intra-group comparison suggested that the PFS was extended for 2.54 months in the treatment group, indicating significant difference between the 2 groups (P=0.00).
1.4 Clinical syndrome differentiation
The clinical syndrome evaluation improvement was elevated for 43.3% in the treatment group when compared with control, indicating significant statistical difference (Z=-2.362, P=0.009).
1.5 Physical status
The KPS score in the treatment group was elevated for 26.6% compared with control group, with statistical difference, (Z=-2.128, P=0.033).
1.6 Safety evaluation
The safety evaluation suggested that the blood routine, liver and kidney function and ECG examination showed no significant different before and after XiaoJiYin treatment. According to the WHO RESIST standard, there was no drop-off case due to intolerable adverse event. There were no hematotoxicity, gastrointestinal symptoms, alopecia or severe cardio, renal or hepato toxicity. Nausea of WHO toxicity grade 1 was observed on the second day of treatment for 3 patients in the treatment group. The symptom disappeared after 10 minutes without handling. Slight diarrhea was observed in on patient after administration of drug for 30 minutes, and was relieved without handling. No treatment-related death was observed.
2 Experimental study
2.1 Effect of different concentration of XiaoJiYin on cell proliferation by MTS method
Different concentration of XiaoJiYin containing serum can suppress proliferation of A549 lung cancer cells. The 72 hours anti-proliferation rate of high concentration XiaoJiYin containing serum on A549 had a significant difference compared with control group.
2.2 The effect of XiaoJiYin in regulating the p-PI3K/p-AKT/mTOR gene expression in human lung cancer cells
The gene expression quantity was recorded after adding different concentration of XiaoJiYin containing serum to A549 cells for 48 and 72 hours. The mRNA expression on BAD and Caspase-9 genes were significantly increased. The 2-ΔΔCt in the high concentration serum for 48 hours group was significantly elevated compared with the control group and had statistical significance (P<0.01). There was no significant difference between experimental groups. In addition, the mRNA expression of mTOR, FKHR and NF-K B was also obviously elevated, and had statistical difference compared with control group (P<0.01) There was no significant difference between experimental groups.
2.3 The effect of XiaoJiYin on the expression of PTEN, PI3K, ATF2 and p-AKT protein through Western Blotting
Through image processing analysis, using GAPDH grey scale as reference, the protein expression of PTEN and phosphor-AKT reduced, PI3K increased yet. Low and medium concentration led to p-PTEN down-regulating, showing significant difference compared with control group (P<0.01). Low and high concentration of XiaoJiYin led to up-regulation of p-PI3K, showing significant difference compared with control group (P<0.01). Medium and high concentration of XiaoJiYin led to down-regulation of p-AKT, showing significant difference compared with control group (P<0.01).
Conclusion
1 Clinical study
Through a prospective randomized control trial (RCT), it was found that the response rate, overall survival and progression-free survival were obviously elevated in XiaoJiYin group compared with the control. The clinical symptoms and physical status were obviously improved, with slight adverse side effects and high safety. Therefore, XiaoJiYin as a maintenance therapy for advanced NSCLC can improve the survival and quality of life.
2 Experimental study
XiaoJiYin containing serum can effectively suppress the proliferation of human lung cancer cell line A549 in vitro, and has certain cytotoxicity. XiaoJiYin can effectively suppress the AKT point in the PI3K/AKT signal transduction pathway, increasing the mRNA expression of downstream molecules like BAD and Caspase-9, enhancing apoptosis of A549 and therefore effectively suppress the growth of A549.
肺癌是全球常见的恶性肿瘤之一,并成为目前人类因癌症死亡的主要原因,是对人类健康与生命危害最大的恶性肿瘤之一。PI3K/AKT/mTOR信号通路在肺癌的发生发展中起着重要的作用,该通路的活化可以抑制多种刺激诱发的细胞凋亡,促进细胞周期进展,从而促进细胞的生长和增殖,同时参与血管形成,在肺癌的形成中扮演重要角色,并参与肿瘤的侵袭和转移。
维持治疗作为延长肺癌患者长期生存的新的重要手段,已引起临床医生的极大重视。晚期非小细胞肺癌的维持治疗临床研究表明,患者经过4-6周期含铂类药物的一线标准联合化疗方案后,疾病无进展且体力状况良好,选择毒副作用较小的药物如细胞毒单药维持化疗或分子靶向药物进行维持治疗可使晚期非小细胞肺癌(NSCLC)患者受益。而中药在维持治疗晚期非小细胞肺癌的领域中的研究尚为数不多,基于长期化疗药物及分子靶向药物维持治疗的毒副反应,中医药可发挥自身优势,探索最佳维持治疗方案。
消积饮作为广东省中医院名老中医刘伟胜教授的多年经验方,已取得了良好的临床疗效,同时亦有多个实验证明该药能够抑制小鼠Lewis肺癌的生长和自发性肺转移、延长荷瘤小鼠的生存期,其作用机制与消积饮降低小鼠Lewis肺癌细胞cyclinDl的表达,影响其细胞周期G1/S调控点,有效地阻止肿瘤细胞周期于G0、G1期,使其不能进入S期进行DNA复制有关。此外,消积饮能有效下调肿瘤细胞PCNA(增殖细胞核抗原)、survivin蛋白及bcl-2基因的表达强度,诱导肿瘤细胞凋亡,降低其转移潜能,从而稳定病灶、减少转移。研究目的：
为探索一条中药维持治疗晚期肺癌的治疗方案,同时深层次挖掘名老中医的学术内涵,从PI3K/AKT/mTOR信号通路探讨消积饮抑制肺癌生长的分子机制亟待进一步研究。
研究内容与方法：
1临床部分
根据纳入标准选入64例经4～6周期化疗后1个月以上,RECIST评价稳定的ⅢB及Ⅳ期NSCLC患者,入组前患者卡氏评分≥60分,无脑转移或脑转移无症状,骨髓、心、肝、肾功能正常。按信封法随机分为治疗组和对照组各32例,治疗组给予消积饮(60ml/m2, po, qd)维持治疗,对照组给予支持治疗,治疗3月后对照统计两组维持治疗的有效率(CR+PR+SD)、临床证候及体力状况、疾病无进展生存期(PFS)及总生存期(OS)。治疗组评价无疾病进展继续治疗及随访观察至疾病进展或死亡。应用SPSS12.0统计分析软件,组间临床特征均衡性评估采用方差分析和PearsornX2检验；组间OS、PFS比较采用Kaplan-Meier分析；治疗后临床证候、体力状况评分取治疗后评估分。组间症状缓解率、体力状况比较采用两个独立样本Mann-Whitney U Test。安全性评价采用描述性统计。
2实验部分
选取人A549肺癌细胞株作为研究对象,生长于RPMI-1640培养液中,细胞传代24h进入对数生长期后分别加入低浓度、中浓度、高浓度含药血清(含消积饮的大鼠血清)及胎牛血清对照组进行细胞诱导。MTS法测定消积饮对A549细胞增殖的抑制作用,Western Blot印迹法检测PI3K/AKT通路p-AKT蛋白的表达,RT-PCR法检测含药血清对PI3K/AKT通路下游分子BAD、Caspase-9、FKHR等基因的mRNA的表达。应用SPSS12.0统计分析软件,组间对照采用单因素方差分析和t检验。
研究结果：
1临床部分
1.1临床特征
64例PSO-2的ⅢB/Ⅳ期非小细胞肺癌患者均来自于广东省中医院肿瘤科住院部,患者于2008年9月到2010年12月纳入研究,治疗前两组基线资料,性别、吸烟史、年龄、分期、KPS评分、入组前化疗等差异均无显著性,组间分布均衡(P>0.05)。共4例出组,治疗组2例因未完成既定治疗出组,对照组2例因主观违背治疗方案出组。实际可评价疗效病例60例,已死亡41例,其余19例正在随访中,按预期计划,经统计学样本数估算,符合疗效评价要求。
1.2近期疗效
治疗3个月后疗效评估,消积饮治疗组有效率达76.7%,对照组有效率达43.3%,两组之间相比具有显著差异(P=0.00)。
1.3生存时间
截止最后随访时间,治疗组和对照组OS分别为6.43个月和3.27个月,组间比较,治疗组的OS延长了3.16个月,两组有明显差异(P=0.00)；治疗组和对照组PFS分别为5.07个月和2.53个月,组间比较,治疗组的PFS延长了2.54个月,两组有明显差异(P=0.00)。
1.4临床证候评分
治疗3个月后,与对照组比较,治疗组临床证候评估改善率提高了43.3%,差异有统计学意义(Z=2.362,P=0.009)。1.5体力状况
治疗3个月后,与对照组比较,治疗组体力状况改善率提高了26.6%,差异有统计学意义(Z=2.128,P=0.033)。
1.6安全性评价安全性评价表明受试者服用消积饮前后血常规,肝、肾功能及心电图检查均未见明显变化。按WHO《实体瘤疗效评定标准和急性和亚急性毒副反应评定标准》,本组病例中没有出现因为不能耐受不良反应而出组的情况。未见相关血液学毒性。未见明显呕吐、腹泻等胃肠道症状、脱发及严重的心、肝、肾功能损害。治疗组3例受试者第2天出现恶心,按WHO毒性分级1级,未经处理,持续约10min,后症状消失；1例受试者服药后约30min出现轻度腹泻,未经处理自行缓解。未出现与治疗相关的死亡。
2实验部分
2.1 MTS法检测含不同浓度消积饮血清对细胞增殖影响的研究
不同浓度的消积饮血清均可抑制人A549肺癌细胞的增殖；高浓度消积饮血清培养人A549肺癌细胞72小时增殖抑制率与对照组相比具有显著差异。
2.2消积饮调控人肺癌细胞p-PI3K/p-AKT/mTOR基因表达的研究
人A549肺癌细胞中加入不同浓度的消积饮血清作用48小时、72小时后记录基因表达量,结果示BAD、Caspase-9基因mRNA的表达量明显增加,作用48小时的高浓度消积饮组2-△△Ct较对照组明显升高,并具有统计学意义(P<0.01)；各实验组之间比较无明显差异。同时,mTOR、NF-κB、FKHR基因mRNA的表达量也明显增加,较对照组也具有统计学意义(P<0.01)；各实验组之间比较无明显差异(P>O.05)。2.3 Western Blotting检测消积饮对PTEN、PI3K及p-AKT蛋白表达的影响
经图像处理分析,以GAPDH的灰度值为参照,PTEN、P13K、磷酸化AKT的蛋白表达减少,PI3K的蛋白表达量增加；其中低、中浓度消积饮组可使p-PTEN表达下调,与对照组相比有明显差异(P<0.01)；低、高浓度消积饮组可使P-PI3K表达上调,与对照组相比有明显差异(P<0.01)；中、高浓度消积饮均可使磷酸化AKT蛋白表达水平下调,与对照组相比具有统计学意义(P<0.01)。
研究结论：
1临床部分
本研究通过前瞻性随机对照试验,消积饮治疗组的有效率较对照组明显升高,中位生存时间及疾病无进展时间较对照组明显延长,临床证候与体力状况较对照组明显改善,毒副反应轻微,安全性评价高。因此,消积饮作为晚期非小细胞肺癌的中药维持治疗方案具有有效低毒的优势,可使晚期NSCLC患者的生存时间及生活质量获益。
2实验部分
消积饮含药血清可在体外有效抑制人肺癌细胞株A549细胞的增殖,具有一定的细胞毒性作用；消积饮可有效抑制PI3K/AKT信号转导通路的AKT位点,增加PI3K/AKT信号转导通路的下游分子BAD、Casepase-9基因mRNA的表达,促进A549肺癌细胞的凋亡,从而有效抑制A549肺癌细肺癌的生长。
Objectives
To investigate a treatment regime of Traditional Chinese Medicine (TCM) as a maintenance therapy for advanced Non-small cell Lung Cancer (NSCLC), to deepen the discovery in the academic content of renowned old TCM practitioner Liu Wei-sheng, and to further investigate the molecular mechanism of XiaoJiYin in suppressing lung cancer growth through the PI3K/AKT/mTOR pathway.
Methods
1 Clinical study
Sixty-four patients of advanced NSCLC were included according to the inclusion criteria, and were randomly divided into treatment group and control group, with 32 patients respectively. In the treatment group, XiaoJiYin was given as a maintenance therapy (60ml/m2, po, qd), while only follow-up and observation was given in the control group (Best support care). After 3 months treatment, the response rate, clinical syndrome scores, KPS scores, overall survival (OS) and progression-free survival (PFS) were compared between the two groups. Variance analysis was performed for the clinical characteristics between groups, while Kaplan-Meier analysis was conducted for the comparison of OS and PFS.
2 Experimental study
Human A549 lung cancer cell line was selected. It was cultivated in RPMI-1640, and XiaoJiYin containing rat serum of low, medium and high concentrations, and fetal bovine serum (FBS) as a control, were added to the cells in logarithmic phase for cell induction. MTS method was used for the suppressive effect of XiaoJiYin in A549 cell proliferation. Western-blot was used for the detection of p-AKT protein in PI3K/AKT pathway, and RT-PCR was used in detecting the expression of downstream mRNA, such as BAD, Caspase-9, FKHR, mTOR and NF-K B in the PI3K/AKT pathway. Variance analysis was performed between groups.
Results
1 Clinical study
1.1 Patient characteristics
The 64 cases of stage IIIB/IV NSCLC patients with PSO-2 were recruited from the In-patient Oncology Department of Guangdong Provincial Hospital of TCM. Patients were enrolled during September 2008 and December 2010. The pre-enrolment baseline characteristics, such as sex, smoking history, age, staging, KPS score and chemotherapy regimens received, had no significant difference and was balanced between groups (P>0.05). Four cases were drop-off, in which the 2 cases in treatment group withdrew due to discontinuation of treatment, while the 2 cases in the control group withdrew because of change in self-decision. There were 60 evaluable cases, 41 cases deceased, while follow-up was conducting. According to the plan, through statistical evaluation of sample number, the requirement of therapeutic evaluation was reached.
1.2 Short-term Efficacy
Therapeutic evaluation was conducted after 3 months of treatment. The response rate (RR) was 76.6% in the treatment group, while the disease control rate (DCR) was 43.3% in the control group. There was significant difference between the 2 groups (P=0.00).
1.3 Survival
Up to the last follow-up, the overall survival (OS) was 6.43 months and 3.27 months in the treatment and control groups respectively. Intra-group comparison suggested that the OS was extended for 3.16 months in the treatment group, indicating significant difference between the 2 groups (P=0.00). The progression-free survivals (PFS) were 5.07 months and 2.53 months in the treatment group and control group respectively. Intra-group comparison suggested that the PFS was extended for 2.54 months in the treatment group, indicating significant difference between the 2 groups (P=0.00).
1.4 Clinical syndrome differentiation
The clinical syndrome evaluation improvement was elevated for 43.3% in the treatment group when compared with control, indicating significant statistical difference (Z=-2.362, P=0.009).
1.5 Physical status
The KPS score in the treatment group was elevated for 26.6% compared with control group, with statistical difference, (Z=-2.128, P=0.033).
1.6 Safety evaluation
The safety evaluation suggested that the blood routine, liver and kidney function and ECG examination showed no significant different before and after XiaoJiYin treatment. According to the WHO RESIST standard, there was no drop-off case due to intolerable adverse event. There were no hematotoxicity, gastrointestinal symptoms, alopecia or severe cardio, renal or hepato toxicity. Nausea of WHO toxicity grade 1 was observed on the second day of treatment for 3 patients in the treatment group. The symptom disappeared after 10 minutes without handling. Slight diarrhea was observed in on patient after administration of drug for 30 minutes, and was relieved without handling. No treatment-related death was observed.
2 Experimental study
2.1 Effect of different concentration of XiaoJiYin on cell proliferation by MTS method
Different concentration of XiaoJiYin containing serum can suppress proliferation of A549 lung cancer cells. The 72 hours anti-proliferation rate of high concentration XiaoJiYin containing serum on A549 had a significant difference compared with control group.
2.2 The effect of XiaoJiYin in regulating the p-PI3K/p-AKT/mTOR gene expression in human lung cancer cells
The gene expression quantity was recorded after adding different concentration of XiaoJiYin containing serum to A549 cells for 48 and 72 hours. The mRNA expression on BAD and Caspase-9 genes were significantly increased. The 2-ΔΔCt in the high concentration serum for 48 hours group was significantly elevated compared with the control group and had statistical significance (P<0.01). There was no significant difference between experimental groups. In addition, the mRNA expression of mTOR, FKHR and NF-K B was also obviously elevated, and had statistical difference compared with control group (P<0.01) There was no significant difference between experimental groups.
2.3 The effect of XiaoJiYin on the expression of PTEN, PI3K, ATF2 and p-AKT protein through Western Blotting
Through image processing analysis, using GAPDH grey scale as reference, the protein expression of PTEN and phosphor-AKT reduced, PI3K increased yet. Low and medium concentration led to p-PTEN down-regulating, showing significant difference compared with control group (P<0.01). Low and high concentration of XiaoJiYin led to up-regulation of p-PI3K, showing significant difference compared with control group (P<0.01). Medium and high concentration of XiaoJiYin led to down-regulation of p-AKT, showing significant difference compared with control group (P<0.01).
Conclusion
1 Clinical study
Through a prospective randomized control trial (RCT), it was found that the response rate, overall survival and progression-free survival were obviously elevated in XiaoJiYin group compared with the control. The clinical symptoms and physical status were obviously improved, with slight adverse side effects and high safety. Therefore, XiaoJiYin as a maintenance therapy for advanced NSCLC can improve the survival and quality of life.
2 Experimental study
XiaoJiYin containing serum can effectively suppress the proliferation of human lung cancer cell line A549 in vitro, and has certain cytotoxicity. XiaoJiYin can effectively suppress the AKT point in the PI3K/AKT signal transduction pathway, increasing the mRNA expression of downstream molecules like BAD and Caspase-9, enhancing apoptosis of A549 and therefore effectively suppress the growth of A549.
引文
[1]顾秀英,胡一河.慢性非传染性疾病预防与控制.北京：中国协和医科大学出版社,2003.210-237
[2]Jemal A, Murray T, Samuels A, et al. Cancer statistics,2003. CA Cancer Clin,2003,53:5-26
[3]World Health Organization. Basic health information on cancer (Revised as of 04 September 2007) [EB/OL]. http://www. wpro. who. Int/information_sources/databases/regional_statist ics/rstat-cancer.htm
[4]王瑾,许峰,周清华.肺癌流行病学研究进展.中国肺癌杂志,2005,8(5)：395-400
[5]沈洪兵,俞顺章.我国肺癌流行现状及其预防对策.中国肿瘤,2004,13(5)：283-285
[6]杨玲,李连弟,陈育德,等.中国肺癌死亡趋势分析及发病、死亡的估计与预测.中国肺癌杂志,2005,8(4)：274-278
[7]Jemal A, Tiwari RC, Murray T, et al. Cancer statistics,2004[J]. CA cancer J Clin,2004,54:8-29
[8]卢君仁,刘伟胜,徐凯,等.消积饮治疗中晚期肺癌的临床观察。广州中医药大学学报,2001,18(3)：195-200
[9]YoshidaM. Discovery of HT LV-1, the first human retro virus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene 2004, 24:5931-5937
[10]牛慧彦,何平.PI3K/AKT/mTOR信号通路在非小细胞肺癌中作用的研究进展.中国全科医学,2007.23(10)：2019-2021
[11]Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer [J]. Sci World J,2004,4:589-604
[12]Massion PP, Tatlan PM, ShyrY, et al. Early involvement of the phosphatidylinositol 3 kinase/AKT pathway in lung cancer progression [J]. Am J Respir Crit Care Med,2004,170(10):1088-1094
[13]Chun KH, Kosmeder II JW, Sun S, et al. Effects of deguelin on the phosphatidylinostol 3-kinase/AKT pathway and apoptosis in premalignant human bronchial epithelial cells [J]. J Natl Cancer Inst,2003, 95(4):291-302
[14]Tsurutani J, Steinberg SM, Ballas M, et al. Prognostic significance of clinical factors and AKT activation in patients with bronchioloalveolar carcinoma [J]. Lung Cancer,2006
[15]Tsurutani J, Fukuoka J, Tsurutani H, et al. Evaluation of two prognostic significance of AKT activation in non-small-cell lung cancer tumors [J]. J Clin Oncol,2006,24(2):306-314
[16]Soung YH, Leo JW, Nam SW, et al. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human [J]. Oncology,2006,70(4):285-289
[17]Tam_guney T, Stokoe D. New insight into PTEN [J]. Cell Science,2007, 120(23):4071-4079
[18]李英红,徐春林,李慧慧.PTEN在非小细胞肺癌中表达及其临床意义[J].哈尔滨医科大学学报,2006,5(8)：394—397
[19]Xin MG, Deng XM. Nicotine Inactivation of the Proapoptotic Function of Bax through Phosphorylation. J Biol Chem,2005;280(11):10781-10789
[20]Song G, Ouyang G, Bao S. The activation of AKT/PKB signaling pathway and survival. J Cell Mol Med,2005;9(1):59-71
[21]Chen ZJ. Ubiquitin signalling in the NF-κB pathway[J]. Nat Cell Biol, 2005,7(8):758-65
[22]柴小姝,吴万垠,刘伟胜.消积饮口服液对小鼠Lewis肺癌生长的抑制作用.中国医学月刊.2004,3(2)：99-100
[23]卢君仁,刘宇龙.消积饮对Lewis肺癌细胞周期影响的实验研究。中医研究,2001,17(3)：38-39
[24]汪波,刘宇龙,石灵春,等.消积饮诱导小鼠Lewis肺癌细胞凋亡及其机理的原位研究。中华中西医杂志,2001,1(1)：1-2
[25]Ganti AK, Huang CH, Klein MA, et al. Lung cancer management in 2010. Oncology (Williston Park).2011 Jan; 25(1):64-73
[26]汪路明,胡坚.肺癌中医药治疗进展。浙江中西医结合杂志,2009,19(12)：777-779
[27]王永炎等.中医内科学(第六版)1994.4
[28]邓宏,刘伟胜.肺癌的中医药治疗进展.新中医,2001,33(4)：73-75
[29]王正昌,肺癌患者三种虚证类型的治疗生存期与血浆环核苷酸水平的关系[J].中西医结合杂志,1984,4(1)：23～24
[30]陈玉琨,蒋梅.肺癌的中医治疗.新中医 1999.05.05；31：31-32
[31]吴林生,陈亚男.周维顺教授论肺癌证治拾萃[J].中华中医药学刊,2007,25(2)：213-214
[32]李和根.刘嘉湘教授以扶正法为主治疗肺癌经验[J].四川中医,2005,23(7)：5-6
[33]洪广祥.原发性支气管肺癌中医药治疗的探讨.江西中医药,1995,26(6)：2-5
[34]黄兆明,陶丽玲.中医药治原发性支气管肺癌概况.江西中医药,1991,22(5)： 51-53
[35]邓海滨,王中奇.徐振晔辨治肺癌经验.四川中医,2002,15(6)：1-2
[36]郁仁存.中医肿瘤学(上册).北京：科学出版社,1997,274-283
[37]周兴兆.唐福安论肺癌证治.浙江中医学院学报,2000,22(4)：45-46
[38]赵炜.李佩文教授治疗肺癌经验介绍[J].新中医,2003,35(11)：9-10
[39]朴炳奎.原发性支气管肺癌中西医结合诊治方案[J].中国肿瘤,1995,4(5)：4-6
[40]周岱翰.肿瘤治验集要[M].广州：广东高教出版社,1997,5-12
[41]刘振东,吴林生.周维顺治疗肺癌经验[J].浙江中医学院学报2004.28(2)：39-40
[42]李峥嵘.中医药辨证分型治疗肺癌125例[J].河南中医学院学报,2004,19(3)：53
[43]孙士玲,杨丽萍.中西医结合治疗晚期非小细胞肺癌疗效观察[J].河南中医,2004 24(3)：51-52
[44]张代钊.肺癌的辨证论治化疗疗效150例临床观察[J].中西医结合杂志2001,22(4)：300301
[45]李雁,刘嘉湘.中药结合化疗治疗非小细胞肺癌的临床研究进展.上海中医药杂志,2002,36(12)：42-44
[46]王维.原发性支气管肺癌的辨证论治.中华实用中西医杂志,2005,18(14)：399-401
[47]孙大兴,裘维焰,赵树珍.肺康方治疗中晚期非小细胞肺癌疗效分析.中医药学报,2002.3(4)：49-50
[48]谢远明,张长富.加味一贯煎治疗肺癌症106例.陕西中医,2002,23(5)302-303
[49]蒋益兰,潘博,仇湘中,等.益肺败毒汤治疗中晚期非小细胞肺癌56例总结.湖南中医杂志2002,18(3)：3-5
[50]刘嘉湘,潘敏求,黎月恒,等.金复康口服液治疗原发性非小细胞肺癌临床研究.肿瘤,2001.21(11)：463-465
[51]刘志臻,余宗阳,欧阳学农,等.中药复方肺泰胶囊维持治疗对中晚期非小细胞肺癌生存质量的影响：随机对照试验.中西医结合学报,2009,7(7)：611-615
[52]李大鹏.康莱特注射液治疗原发性肺癌临床报告.中医杂志1996,37：411-414
[53]周黎明,周建军,洪节约,等.康莱特注射液治疗化疗失败的晚期非小细胞肺癌.实用肿瘤杂志 1999,14(10)：313-314
[54]花海兵,林苏.消徵膏治疗肺癌疼痛60例.中医外治杂志 1999,8(2)：16
[55]杨葆康,姜仁成.灵仙丹熏吸疗法治疗中晚期肺癌66例.辽宁中医杂志 1994,21(1)：3
[56]陈良良,谢光尧,江克文.针灸对肺癌患者的免疫调节作用.中国针灸.1997,17(2)：197-199
[57]王晓红,唐梦熊,江澜,等.足三里穴注治疗化疗致白细胞下降临床观察.内蒙古中医药,1995,14(8)：33
[58]李斯文,石颖,李晓林,等.肿瘤康胶囊辅助治疗非小细胞肺癌的Ⅲ期临床研究.临床肿瘤学杂志,2010,15(6)：545-548
[59]蔡红兵,代方国,闵清芬等.中医药配合放疗治疗肺的临床研究.第一军医大学学报,2002,22(12)：1112
[60]朱惠蓉,刘嘉湘,等.益肺抗瘤饮对Lewis肺癌荷瘤小鼠神经内分泌免疫的实验研究.上海中医药大学学报,2000,14(6)：44-46
[61]刘嘉湘,施志明,徐振晔,等.金复康口服液治疗非小细胞肺癌的临床观察[J].中医杂志,1997,38(12)：727
[62]朱惠蓉,刘嘉湘.益肺抗瘤饮治疗晚期肺癌28例临床观察[J].湖南中医杂志,2000,16(3)：9
[63]郭琳.中药扶正方抗小鼠Lewis肺癌自发性肺转移及对红细胞免疫影响的实验研究.中华实用中西医杂志,2006,19(11)：1299-1300,1302
[64]吴继,徐振晔,王中奇,等.中药肺岩宁方治疗晚期非小细胞肺癌疗效观察—对血清CEA CYFRA21-1及免疫功能的影响.辽宁中医,2008,35(11)：1707-1708
[65]陈坚.中药抗肺癌转移的实验研究进展.医学综述,2008,14(1)：82-83
[66]汪波,谭敏,张维彬,等.中药组方抑制lewis肺癌细胞转移及机理研究.中国自然医学杂志,2001,8(3)：130-133
[67]刘嘉湘,施志明,李和根,等.益肺抗瘤饮治疗271例非小细胞肺癌临床观察.上海中医药杂志,2001,35(2)：4-6
[68]张培彤,裴迎霞,祁鑫,等.活血药对人肺癌细胞粘附和侵袭的影响[J].中国中西医结合杂志,1999,19(2)：103
[69]李妍,鞠晓红,任旷,等.几种中药单体抑制非小细胞肺癌增殖的实验研究.时珍国医国药,2009,20(9)：2163-2164
[70]李京,黎杏群,李家邦.扶正保真汤对恶性肿瘤放、化疗增效作用的临床与实验研究.中国中西医结合杂志,1998,18(9)：523-526
[71]张维彬,汪波,刘宇龙,等.扶正祛邪方抑制肺癌细胞周期及其机制的实验研究.广州中医药大学学报,2001,18(12)：346-349
[72]王苗,董坚,李秋恬,等.植物中药IHA-01抑制人肺癌GLC细胞增殖和诱导凋亡的实验研究.中国医药生物技术,2010,2：105-109
[73]许磊.晚期非小细胞肺癌中药治疗前后肿瘤细胞凋亡的对比观察.上海医药, 1997,21(3)：44
[74]杨勤建,涂晋文.化痰散结方含药血清诱导人肺癌细胞凋亡的机理研究.北京中医药大学学报,1999,22(9)：70-72
[75]钱军,秦叔逵,杨爱珍,等.榄香烯乳逆转人肺癌细胞的实验研究[J].肿瘤防治研究,1996,23(5)：299
[76]Rinaldi M, Belvedere 0, Cauchi C, et al. Maintenance chemotherapy in non-small cell lung cancer[J]. Ann Oncol,2006,17(Suppl 2):ii67-ii70
[77]Grossi F, Aita M, Foilador A, et al. Sequential, alternating, and maintenance /consolidation chemotherapy in advaneed non-small cell lung cancer:a review for the literature[J]. Oncologist,2007,12(4):451-464
[78]Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate[J]. Cancer Treat Rep,1979,63(11-12):1727-1733
[79]Belani CP, Perry MC, La Rocca RV, et al. Maintenance therapy with weekly paclitaxel improves outcome for advanced non-small cell lung cancer patients[J]. Proc AmSoc Clin Oncol,2005,23:7143
[80]Brodowicz T, Krzakowski M,Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemeitabine or best supportive care in advanced non-small cell lung cancer:a phase III trial[J]. Lung Cancer,2006,52(2):155-163
[81]Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer[J]. J Natl Cancer Inst,2005,97(7):499-506
[82]Fathi AT, Brahmer JR. Chemotherapy for advanced stage non-small cell lung cancer. Semin Thorac Cardiovasc Surg.2008; 20(3):210-216
[83]Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN:A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC[J]. J Clin Oncol,2009,27:8001
[84]Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy inpatients(pts)with advanced non-small cell lung cancer (NSCLC):results of West Japan Thoracic Oncology Grouptrial(WJTOG) [J]. J Clin Oncol,2008,26(15S):LBA8012
[85]Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer:a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol.2010 Jun;11 (6):521-9.
[86]Hida T, Ogawa S, Park JC, et al. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther.2009 Jan;9(1):17-35
[87]刘志臻,余宗阳,欧阳学农等.中药复方肺泰胶囊维持治疗对中晚期非小细胞肺癌生存质量的影响：随机对照试验.中西医结合学报.2009；7(7)：611-615
[88]刘志臻,余宗阳,欧阳学农等.肺泰胶囊维持治疗对中晚期非小细胞肺癌无进展生存期的影响.临床肿瘤学杂志.2009；14(4)：344-346
[89]孙晓杰,黄常志.PI3K-AKT信号通路与肿瘤.世界华人消化杂志,2006；14(3)：306-311
[90]孙继萍,肖伟.黄芪对人肺癌细胞株IL-2及IFN-γ的诱生作用[J].山东医药2000；40：9-10
[91]隋道敬,邵敏,刘安.黄芪口服液治疗恶性肿瘤60例的疗效观察[J].上海医药1998；19：13-14
[92]郭江宁,吴侯,翁新楚,等.补骨脂中活性成分的提取分离与抗癌实验研究.中药材2003；26：185-187
[93]刘燕,林瑞超,李波.云芝多糖抗肿瘤作用研究进展.中成药2001；23：755-757.
[94]Li Rui, Zhao Haoru and Lin Yining. Anti-tumor Effect and Protective Effect on Chemotherapeutic Damage of Water Soluble Extracts from Hedyotis diffusa. Journal of Chinese Phamaceutical Sciences 2002;11:54-58
[95]单保恩,张金艳,杜肖娜,等.白花蛇舌草的免疫学调节活性和抗肿瘤活性.中国中西医结合杂志2001；21：370-374
[96]张敏,刘玉宝.具有抗肿瘤作用的虫类中药.现代中西医结合杂志2000；9：1190-1191
[97]曲爱兵,赵维诚,梁良,等.蜈蚣组织提取物抗肿瘤活性的初步研究.实用肿瘤学杂志2003；17：29-30
[98]程仁权,程建萍,贾正红,等.全蝎治疗肿瘤的研究.中国中西医结合外科杂志2002；8：360
[99]唐小江,祝寿芬.山大黄多糖的抗肿瘤及免疫增强作用.中药药理与临床1999；15：27-29
[100]吴万垠,柴小姝,李新等.中药联合长春瑞滨治疗46例老年ⅢB/Ⅳ期非小细胞肺癌.癌症进展2007；5(5)：425-430
[101]张海波,吴万垠,柴小姝等.中药联合长春瑞滨治疗31例PS评分2.0的Ⅲ B/Ⅳ期非小细胞肺癌.上海中医药杂志 2006；40(7)：30-32
[102]柴小姝,吴万垠,刘伟胜.消积饮口服液对小鼠Lewis肺癌生长的抑制作用.中国医学月刊.2004,3(2)：99-100
[103]卢君仁,刘宇龙.消积饮对Lewis肺癌细胞周期影响的实验研究。中医研究,2001,17(3)：38-39
[104]汪波,刘宇龙,石灵春,等.消积饮诱导小鼠Lewis肺癌细胞凋亡及其机理的原位研究。中华中西医杂志,2001,1(1)：1-2
[105]黎云,汪波,贾军,李伟星,肖焕.消积饮对肺癌移植瘤的抑制作用及机理研究。中药药理与临床2005.04.15；21(2)：34-36
[106]吴万垠,柴小姝,张海波等.中药联合长春瑞滨对小鼠Lewis肺癌细胞周期及细胞增殖抗原的影响.广东医学2006；27(8)：1154-1156
[107]郑筱萸.中药新药临床研究指导原则[].北京：中国医药科技出版社,2002.216-221
[108]Scagliotti GV, Marinis FD, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer[J]. J Clin Oncol.2002,20:4285-4291
[109]Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med,2002,346(2):92-98
[110]Fidias PM, Dakhil SR, Lyss AP, et al. Phase IU study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer [J]. J Clin Oncol,2009, 27(4):591-598.
[111]Scagliotti GV, Parikh P, von Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol.2008,26(21):3543-3551
[112]Lee S, Ignacio J, Yu C, et al. FAST-ACT:A phase Ⅱ randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage Ⅳ B/Ⅳ non-small cell lung cancer(NSCLC)[J]. J Clin Oncol.2008,26:8031.
[113]林丽珠,周岱翰,郑心婷.中医药提高晚期非小细胞肺癌患者生存质量的临床观察.中国中西医结合杂志.2006,26(5)：389-393
[114]周雍明,朴炳奎,侯炜等.肺瘤平膏改善非小细胞肺癌患者免疫状态及预后的临床观察.中国中医药信息杂志.2008,15(5)：78—79
[115]Mosmann T. Rapid colofimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays[J]. J Immunol Methods,1983,65(1-2):55-65
[116]Rollino C, Borsa S, Bellone G. False positive results with MTT assay[J]. J Immunol Methods,1995,185(1):141-143
[117]MTS法在肿瘤药敏试验中的研究进展.江西医学检验,2005,23(3)：252,285
[118]Cory S, Adams JM. The Bcl-2 family:regulators of the cellular life-or-death switch[J]. Natl Rev Cancer.2002,2:647-656
[119]Datta SR, Anne Brunet A, Greenberg ME. Cellular survival:a play in three AKTs[J]. Genes Dev,1999,13(22):2905-2927
[120]Bjornsti MA, Houghton PJ. The TOR pathway:a target for cancer therapy. Nat Rev Cancer,2oo4,4(5):335-348
[121]Gera JF,Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and C-myc expression. J Biol Chem,2004.279(4):2737-2746
[2]Jemal A, Murray T, Samuels A, et al. Cancer statistics,2003. CA Cancer Clin,2003,53:5-26
[3]World Health Organization. Basic health information on cancer (Revised as of 04 September 2007) [EB/OL]. http://www. wpro. who. Int/information_sources/databases/regional_statist ics/rstat-cancer.htm
[4]王瑾,许峰,周清华.肺癌流行病学研究进展.中国肺癌杂志,2005,8(5)：395-400
[5]沈洪兵,俞顺章.我国肺癌流行现状及其预防对策.中国肿瘤,2004,13(5)：283-285
[6]杨玲,李连弟,陈育德,等.中国肺癌死亡趋势分析及发病、死亡的估计与预测.中国肺癌杂志,2005,8(4)：274-278
[7]Jemal A, Tiwari RC, Murray T, et al. Cancer statistics,2004[J]. CA cancer J Clin,2004,54:8-29
[8]卢君仁,刘伟胜,徐凯,等.消积饮治疗中晚期肺癌的临床观察。广州中医药大学学报,2001,18(3)：195-200
[9]YoshidaM. Discovery of HT LV-1, the first human retro virus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene 2004, 24:5931-5937
[10]牛慧彦,何平.PI3K/AKT/mTOR信号通路在非小细胞肺癌中作用的研究进展.中国全科医学,2007.23(10)：2019-2021
[11]Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer [J]. Sci World J,2004,4:589-604
[12]Massion PP, Tatlan PM, ShyrY, et al. Early involvement of the phosphatidylinositol 3 kinase/AKT pathway in lung cancer progression [J]. Am J Respir Crit Care Med,2004,170(10):1088-1094
[13]Chun KH, Kosmeder II JW, Sun S, et al. Effects of deguelin on the phosphatidylinostol 3-kinase/AKT pathway and apoptosis in premalignant human bronchial epithelial cells [J]. J Natl Cancer Inst,2003, 95(4):291-302
[14]Tsurutani J, Steinberg SM, Ballas M, et al. Prognostic significance of clinical factors and AKT activation in patients with bronchioloalveolar carcinoma [J]. Lung Cancer,2006
[15]Tsurutani J, Fukuoka J, Tsurutani H, et al. Evaluation of two prognostic significance of AKT activation in non-small-cell lung cancer tumors [J]. J Clin Oncol,2006,24(2):306-314
[16]Soung YH, Leo JW, Nam SW, et al. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human [J]. Oncology,2006,70(4):285-289
[17]Tam_guney T, Stokoe D. New insight into PTEN [J]. Cell Science,2007, 120(23):4071-4079
[18]李英红,徐春林,李慧慧.PTEN在非小细胞肺癌中表达及其临床意义[J].哈尔滨医科大学学报,2006,5(8)：394—397
[19]Xin MG, Deng XM. Nicotine Inactivation of the Proapoptotic Function of Bax through Phosphorylation. J Biol Chem,2005;280(11):10781-10789
[20]Song G, Ouyang G, Bao S. The activation of AKT/PKB signaling pathway and survival. J Cell Mol Med,2005;9(1):59-71
[21]Chen ZJ. Ubiquitin signalling in the NF-κB pathway[J]. Nat Cell Biol, 2005,7(8):758-65
[22]柴小姝,吴万垠,刘伟胜.消积饮口服液对小鼠Lewis肺癌生长的抑制作用.中国医学月刊.2004,3(2)：99-100
[23]卢君仁,刘宇龙.消积饮对Lewis肺癌细胞周期影响的实验研究。中医研究,2001,17(3)：38-39
[24]汪波,刘宇龙,石灵春,等.消积饮诱导小鼠Lewis肺癌细胞凋亡及其机理的原位研究。中华中西医杂志,2001,1(1)：1-2
[25]Ganti AK, Huang CH, Klein MA, et al. Lung cancer management in 2010. Oncology (Williston Park).2011 Jan; 25(1):64-73
[26]汪路明,胡坚.肺癌中医药治疗进展。浙江中西医结合杂志,2009,19(12)：777-779
[27]王永炎等.中医内科学(第六版)1994.4
[28]邓宏,刘伟胜.肺癌的中医药治疗进展.新中医,2001,33(4)：73-75
[29]王正昌,肺癌患者三种虚证类型的治疗生存期与血浆环核苷酸水平的关系[J].中西医结合杂志,1984,4(1)：23～24
[30]陈玉琨,蒋梅.肺癌的中医治疗.新中医 1999.05.05；31：31-32
[31]吴林生,陈亚男.周维顺教授论肺癌证治拾萃[J].中华中医药学刊,2007,25(2)：213-214
[32]李和根.刘嘉湘教授以扶正法为主治疗肺癌经验[J].四川中医,2005,23(7)：5-6
[33]洪广祥.原发性支气管肺癌中医药治疗的探讨.江西中医药,1995,26(6)：2-5
[34]黄兆明,陶丽玲.中医药治原发性支气管肺癌概况.江西中医药,1991,22(5)： 51-53
[35]邓海滨,王中奇.徐振晔辨治肺癌经验.四川中医,2002,15(6)：1-2
[36]郁仁存.中医肿瘤学(上册).北京：科学出版社,1997,274-283
[37]周兴兆.唐福安论肺癌证治.浙江中医学院学报,2000,22(4)：45-46
[38]赵炜.李佩文教授治疗肺癌经验介绍[J].新中医,2003,35(11)：9-10
[39]朴炳奎.原发性支气管肺癌中西医结合诊治方案[J].中国肿瘤,1995,4(5)：4-6
[40]周岱翰.肿瘤治验集要[M].广州：广东高教出版社,1997,5-12
[41]刘振东,吴林生.周维顺治疗肺癌经验[J].浙江中医学院学报2004.28(2)：39-40
[42]李峥嵘.中医药辨证分型治疗肺癌125例[J].河南中医学院学报,2004,19(3)：53
[43]孙士玲,杨丽萍.中西医结合治疗晚期非小细胞肺癌疗效观察[J].河南中医,2004 24(3)：51-52
[44]张代钊.肺癌的辨证论治化疗疗效150例临床观察[J].中西医结合杂志2001,22(4)：300301
[45]李雁,刘嘉湘.中药结合化疗治疗非小细胞肺癌的临床研究进展.上海中医药杂志,2002,36(12)：42-44
[46]王维.原发性支气管肺癌的辨证论治.中华实用中西医杂志,2005,18(14)：399-401
[47]孙大兴,裘维焰,赵树珍.肺康方治疗中晚期非小细胞肺癌疗效分析.中医药学报,2002.3(4)：49-50
[48]谢远明,张长富.加味一贯煎治疗肺癌症106例.陕西中医,2002,23(5)302-303
[49]蒋益兰,潘博,仇湘中,等.益肺败毒汤治疗中晚期非小细胞肺癌56例总结.湖南中医杂志2002,18(3)：3-5
[50]刘嘉湘,潘敏求,黎月恒,等.金复康口服液治疗原发性非小细胞肺癌临床研究.肿瘤,2001.21(11)：463-465
[51]刘志臻,余宗阳,欧阳学农,等.中药复方肺泰胶囊维持治疗对中晚期非小细胞肺癌生存质量的影响：随机对照试验.中西医结合学报,2009,7(7)：611-615
[52]李大鹏.康莱特注射液治疗原发性肺癌临床报告.中医杂志1996,37：411-414
[53]周黎明,周建军,洪节约,等.康莱特注射液治疗化疗失败的晚期非小细胞肺癌.实用肿瘤杂志 1999,14(10)：313-314
[54]花海兵,林苏.消徵膏治疗肺癌疼痛60例.中医外治杂志 1999,8(2)：16
[55]杨葆康,姜仁成.灵仙丹熏吸疗法治疗中晚期肺癌66例.辽宁中医杂志 1994,21(1)：3
[56]陈良良,谢光尧,江克文.针灸对肺癌患者的免疫调节作用.中国针灸.1997,17(2)：197-199
[57]王晓红,唐梦熊,江澜,等.足三里穴注治疗化疗致白细胞下降临床观察.内蒙古中医药,1995,14(8)：33
[58]李斯文,石颖,李晓林,等.肿瘤康胶囊辅助治疗非小细胞肺癌的Ⅲ期临床研究.临床肿瘤学杂志,2010,15(6)：545-548
[59]蔡红兵,代方国,闵清芬等.中医药配合放疗治疗肺的临床研究.第一军医大学学报,2002,22(12)：1112
[60]朱惠蓉,刘嘉湘,等.益肺抗瘤饮对Lewis肺癌荷瘤小鼠神经内分泌免疫的实验研究.上海中医药大学学报,2000,14(6)：44-46
[61]刘嘉湘,施志明,徐振晔,等.金复康口服液治疗非小细胞肺癌的临床观察[J].中医杂志,1997,38(12)：727
[62]朱惠蓉,刘嘉湘.益肺抗瘤饮治疗晚期肺癌28例临床观察[J].湖南中医杂志,2000,16(3)：9
[63]郭琳.中药扶正方抗小鼠Lewis肺癌自发性肺转移及对红细胞免疫影响的实验研究.中华实用中西医杂志,2006,19(11)：1299-1300,1302
[64]吴继,徐振晔,王中奇,等.中药肺岩宁方治疗晚期非小细胞肺癌疗效观察—对血清CEA CYFRA21-1及免疫功能的影响.辽宁中医,2008,35(11)：1707-1708
[65]陈坚.中药抗肺癌转移的实验研究进展.医学综述,2008,14(1)：82-83
[66]汪波,谭敏,张维彬,等.中药组方抑制lewis肺癌细胞转移及机理研究.中国自然医学杂志,2001,8(3)：130-133
[67]刘嘉湘,施志明,李和根,等.益肺抗瘤饮治疗271例非小细胞肺癌临床观察.上海中医药杂志,2001,35(2)：4-6
[68]张培彤,裴迎霞,祁鑫,等.活血药对人肺癌细胞粘附和侵袭的影响[J].中国中西医结合杂志,1999,19(2)：103
[69]李妍,鞠晓红,任旷,等.几种中药单体抑制非小细胞肺癌增殖的实验研究.时珍国医国药,2009,20(9)：2163-2164
[70]李京,黎杏群,李家邦.扶正保真汤对恶性肿瘤放、化疗增效作用的临床与实验研究.中国中西医结合杂志,1998,18(9)：523-526
[71]张维彬,汪波,刘宇龙,等.扶正祛邪方抑制肺癌细胞周期及其机制的实验研究.广州中医药大学学报,2001,18(12)：346-349
[72]王苗,董坚,李秋恬,等.植物中药IHA-01抑制人肺癌GLC细胞增殖和诱导凋亡的实验研究.中国医药生物技术,2010,2：105-109
[73]许磊.晚期非小细胞肺癌中药治疗前后肿瘤细胞凋亡的对比观察.上海医药, 1997,21(3)：44
[74]杨勤建,涂晋文.化痰散结方含药血清诱导人肺癌细胞凋亡的机理研究.北京中医药大学学报,1999,22(9)：70-72
[75]钱军,秦叔逵,杨爱珍,等.榄香烯乳逆转人肺癌细胞的实验研究[J].肿瘤防治研究,1996,23(5)：299
[76]Rinaldi M, Belvedere 0, Cauchi C, et al. Maintenance chemotherapy in non-small cell lung cancer[J]. Ann Oncol,2006,17(Suppl 2):ii67-ii70
[77]Grossi F, Aita M, Foilador A, et al. Sequential, alternating, and maintenance /consolidation chemotherapy in advaneed non-small cell lung cancer:a review for the literature[J]. Oncologist,2007,12(4):451-464
[78]Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate[J]. Cancer Treat Rep,1979,63(11-12):1727-1733
[79]Belani CP, Perry MC, La Rocca RV, et al. Maintenance therapy with weekly paclitaxel improves outcome for advanced non-small cell lung cancer patients[J]. Proc AmSoc Clin Oncol,2005,23:7143
[80]Brodowicz T, Krzakowski M,Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemeitabine or best supportive care in advanced non-small cell lung cancer:a phase III trial[J]. Lung Cancer,2006,52(2):155-163
[81]Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer[J]. J Natl Cancer Inst,2005,97(7):499-506
[82]Fathi AT, Brahmer JR. Chemotherapy for advanced stage non-small cell lung cancer. Semin Thorac Cardiovasc Surg.2008; 20(3):210-216
[83]Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN:A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC[J]. J Clin Oncol,2009,27:8001
[84]Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy inpatients(pts)with advanced non-small cell lung cancer (NSCLC):results of West Japan Thoracic Oncology Grouptrial(WJTOG) [J]. J Clin Oncol,2008,26(15S):LBA8012
[85]Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer:a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol.2010 Jun;11 (6):521-9.
[86]Hida T, Ogawa S, Park JC, et al. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther.2009 Jan;9(1):17-35
[87]刘志臻,余宗阳,欧阳学农等.中药复方肺泰胶囊维持治疗对中晚期非小细胞肺癌生存质量的影响：随机对照试验.中西医结合学报.2009；7(7)：611-615
[88]刘志臻,余宗阳,欧阳学农等.肺泰胶囊维持治疗对中晚期非小细胞肺癌无进展生存期的影响.临床肿瘤学杂志.2009；14(4)：344-346
[89]孙晓杰,黄常志.PI3K-AKT信号通路与肿瘤.世界华人消化杂志,2006；14(3)：306-311
[90]孙继萍,肖伟.黄芪对人肺癌细胞株IL-2及IFN-γ的诱生作用[J].山东医药2000；40：9-10
[91]隋道敬,邵敏,刘安.黄芪口服液治疗恶性肿瘤60例的疗效观察[J].上海医药1998；19：13-14
[92]郭江宁,吴侯,翁新楚,等.补骨脂中活性成分的提取分离与抗癌实验研究.中药材2003；26：185-187
[93]刘燕,林瑞超,李波.云芝多糖抗肿瘤作用研究进展.中成药2001；23：755-757.
[94]Li Rui, Zhao Haoru and Lin Yining. Anti-tumor Effect and Protective Effect on Chemotherapeutic Damage of Water Soluble Extracts from Hedyotis diffusa. Journal of Chinese Phamaceutical Sciences 2002;11:54-58
[95]单保恩,张金艳,杜肖娜,等.白花蛇舌草的免疫学调节活性和抗肿瘤活性.中国中西医结合杂志2001；21：370-374
[96]张敏,刘玉宝.具有抗肿瘤作用的虫类中药.现代中西医结合杂志2000；9：1190-1191
[97]曲爱兵,赵维诚,梁良,等.蜈蚣组织提取物抗肿瘤活性的初步研究.实用肿瘤学杂志2003；17：29-30
[98]程仁权,程建萍,贾正红,等.全蝎治疗肿瘤的研究.中国中西医结合外科杂志2002；8：360
[99]唐小江,祝寿芬.山大黄多糖的抗肿瘤及免疫增强作用.中药药理与临床1999；15：27-29
[100]吴万垠,柴小姝,李新等.中药联合长春瑞滨治疗46例老年ⅢB/Ⅳ期非小细胞肺癌.癌症进展2007；5(5)：425-430
[101]张海波,吴万垠,柴小姝等.中药联合长春瑞滨治疗31例PS评分2.0的Ⅲ B/Ⅳ期非小细胞肺癌.上海中医药杂志 2006；40(7)：30-32
[102]柴小姝,吴万垠,刘伟胜.消积饮口服液对小鼠Lewis肺癌生长的抑制作用.中国医学月刊.2004,3(2)：99-100
[103]卢君仁,刘宇龙.消积饮对Lewis肺癌细胞周期影响的实验研究。中医研究,2001,17(3)：38-39
[104]汪波,刘宇龙,石灵春,等.消积饮诱导小鼠Lewis肺癌细胞凋亡及其机理的原位研究。中华中西医杂志,2001,1(1)：1-2
[105]黎云,汪波,贾军,李伟星,肖焕.消积饮对肺癌移植瘤的抑制作用及机理研究。中药药理与临床2005.04.15；21(2)：34-36
[106]吴万垠,柴小姝,张海波等.中药联合长春瑞滨对小鼠Lewis肺癌细胞周期及细胞增殖抗原的影响.广东医学2006；27(8)：1154-1156
[107]郑筱萸.中药新药临床研究指导原则[].北京：中国医药科技出版社,2002.216-221
[108]Scagliotti GV, Marinis FD, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer[J]. J Clin Oncol.2002,20:4285-4291
[109]Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med,2002,346(2):92-98
[110]Fidias PM, Dakhil SR, Lyss AP, et al. Phase IU study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer [J]. J Clin Oncol,2009, 27(4):591-598.
[111]Scagliotti GV, Parikh P, von Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol.2008,26(21):3543-3551
[112]Lee S, Ignacio J, Yu C, et al. FAST-ACT:A phase Ⅱ randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage Ⅳ B/Ⅳ non-small cell lung cancer(NSCLC)[J]. J Clin Oncol.2008,26:8031.
[113]林丽珠,周岱翰,郑心婷.中医药提高晚期非小细胞肺癌患者生存质量的临床观察.中国中西医结合杂志.2006,26(5)：389-393
[114]周雍明,朴炳奎,侯炜等.肺瘤平膏改善非小细胞肺癌患者免疫状态及预后的临床观察.中国中医药信息杂志.2008,15(5)：78—79
[115]Mosmann T. Rapid colofimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays[J]. J Immunol Methods,1983,65(1-2):55-65
[116]Rollino C, Borsa S, Bellone G. False positive results with MTT assay[J]. J Immunol Methods,1995,185(1):141-143
[117]MTS法在肿瘤药敏试验中的研究进展.江西医学检验,2005,23(3)：252,285
[118]Cory S, Adams JM. The Bcl-2 family:regulators of the cellular life-or-death switch[J]. Natl Rev Cancer.2002,2:647-656
[119]Datta SR, Anne Brunet A, Greenberg ME. Cellular survival:a play in three AKTs[J]. Genes Dev,1999,13(22):2905-2927
[120]Bjornsti MA, Houghton PJ. The TOR pathway:a target for cancer therapy. Nat Rev Cancer,2oo4,4(5):335-348
[121]Gera JF,Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and C-myc expression. J Biol Chem,2004.279(4):2737-2746